These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 23286429)

  • 1. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
    Kozlowski D; Budrejko S; Raczak G; Rysz J; Banach M
    Curr Pharm Des; 2013; 19(21):3816-26. PubMed ID: 23286429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with vitamin K antagonists in patients with nonvalvular atrial fibrillation: a systematic literature review.
    Briere JB; Bowrin K; Coleman C; Fauchier L; Levy P; Folkerts K; Toumi M; Taieb V; Millier A; Wu O
    Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):27-36. PubMed ID: 30169975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [New treatments for stroke and thromboembolism prevention in atrial fibrillation].
    Shiyovich A; Khalameizer V; Katz A
    Harefuah; 2014 Jan; 153(1):32-8, 64. PubMed ID: 24605405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
    Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
    Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel anticoagulants for stroke prevention in patients with atrial fibrillation.
    Jalota A; Scarabelli TM; Saravolatz L; Bakhsh MU; Agrawal P; Jalota R; Chen-Scarabelli C; Fuster V; Halperin J
    Cardiovasc Drugs Ther; 2014 Jun; 28(3):247-62. PubMed ID: 24842559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
    Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
    Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?
    Dzeshka MS; Lip GY
    Trends Cardiovasc Med; 2015 May; 25(4):315-36. PubMed ID: 25440108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new era for anticoagulation in atrial fibrillation. Which anticoagulant should we choose for long‑term prevention of thromboembolic complications in patients with atrial fibrillation?
    Riva N; Lip GY
    Pol Arch Med Wewn; 2012; 122(1-2):45-53. PubMed ID: 22353706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Use of Apixaban for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Proietti M; Romanazzi I; Romiti GF; Farcomeni A; Lip GYH
    Stroke; 2018 Jan; 49(1):98-106. PubMed ID: 29167388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation.
    Ment J
    Vasc Health Risk Manag; 2015; 11():317-32. PubMed ID: 26089678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
    Saliba W
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):323-35. PubMed ID: 26055615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.